Pharmacological therapies used to treat RP complications, such as CME, rely primarily on carbonic anhydrase inhibitors as a first-line treatment, with corticosteroids, VEGF inhibitors, and anti-inflammatory drugs serving as second-line therapies. This evidence concerns the gene VEGFA and retinitis pigmentosa 1.